Bristol-Myers Squibb Acquisition History Continues With MRTX

 Bristol-Myers Squibb was founded in 1858 and has grown to be one of today’s leading global pharmaceutical companies. Bristol-Myers Squibb acquisition history goes back as far as around 160 years. For over 160 years, Bristol-Myers Squibb (BMS) has been committed to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases.”

How Bristol-Myers Squibb acquisition history started?

Bristol-Myers Squibb main focus is addressing serious diseases in areas of significant unmet medical need. Its research and development efforts concentrate on the following six core therapeutic areas: cardiovascular, immunoscience, metabolics, neuroscience, oncology and virology. According to BMS, its pipeline is “one of the most innovative in the industry”. But before we learn more about the medicines the company is developing, let’s take a look at its history.

Bristol-Myers Squibb acquisition history dates back to 1943. Bristol-Myers acquired a New York manufacturer of acidophilus milk, called Cheplin Laboratories. Till today, when Bristol-Myers Squibb acquisitions will include cancer drugmaker Mirati Therapeutics.

Latest Bristol-Myers Squibb acquisition

Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics (NASDAQ:MRTX) for up to $5.8 billion, diversifying its oncology business. They will also be adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.

Overview of acquisitions history of Bristol-Myers Squibb

Bristol-Myers Squibb has made 20 acquisitions across sectors such as Biopharmaceuticals, Life Sciences – U.S., Immunotherapy and others. The company has spent over $101B for acquisitions.

List of Acquisitions of Bristol-Myers Squibb

Notable Acquisitions of Bristol-Myers Squibb

Here are the top 5 acquisitions of Bristol-Myers Squibb:

Recent Acquisitions of Bristol-Myers Squibb

Here are the 3 new acquisitions of Bristol-Myers Squibb:

All about the newest acquisition by Bristol-Myers Squibb

Bristol will pick up Mirati’s po.1Brtfolio drugs that target the genetic drivers of specific cancers including its lung cancer drug, Krazati, which was approved in December.

A second compound – MRTX1719 – which could be used in some types of lung cancer was also attractive to the company, Bristol executives said in an interview.

“We think this really helps strategically complement our oncology portfolio but also, from a financial standpoint, it helps out commercially in the back half of the decade,” said Adam Lenkowsky, Bristol’s Chief Commercialization Officer.

Last year, Bristol acquired drug developer Turning Point Therapeutics (NASDAQ:TPTX) for $4.1 billion in cash to help bolster its arsenal of cancer drugs.